Bio-Rad Laboratories (NYSE:BIO) Releases Quarterly Earnings Results, Beats Expectations By $0.42 EPS

Bio-Rad Laboratories (NYSE:BIO) issued its earnings results on Wednesday. The medical research company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.42, FiscalAI reports. The business had revenue of $656.40 million during the quarter, compared to analysts’ expectations of $649.94 million. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%. Bio-Rad Laboratories’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.26 EPS.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

• Bio-Rad returned to modest currency-neutral growth in Q3, with revenue up 0.7%. Non-GAAP gross margin rose to 54.5% from 53.5% a year earlier, and non-GAAP diluted EPS increased to $2.65 from $2.26.
• ddPCR remained a growth driver: portfolio revenue rose 7% currency-neutral, while instrument revenue increased more than 20% for a third consecutive quarter. Management said placements and competitive wins support the opportunity, though consumable pull-through has not yet normalized and may remain soft into 2027.
• Bio-Rad reaffirmed 2026 currency-neutral revenue growth guidance of -3% to +0.5%, expecting results near the midpoint. It anticipates continued academic and government market weakness, a Q4 sequential decline in gross margin, and a sequential decline in process chromatography revenue.
• Management cited ongoing market pressures, including NIH outlays down about 15% year over year in Q3 and pricing pressure in China. It estimates China’s updated healthcare guidelines could reduce 2027 revenue by a mid-single-digit millions of dollars amount; elevated Middle East logistics costs may also persist into 2027.
• Management said it is focused on returning to positive revenue growth and expanding margins in 2027, while cautioning that the recovery may not be fully normalized. The restructuring program is expected to deliver $30 million–$35 million in savings, with full benefits beginning in 2028.

Bio-Rad Laboratories Trading Down 2.7%

Shares of Bio-Rad Laboratories stock traded down $10.08 during trading on Thursday, reaching $369.91. 202,694 shares of the company were exchanged, compared to its average volume of 305,637. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $9.89 billion, a price-to-earnings ratio of 44.64 and a beta of 1.06. The business has a 50-day moving average price of $374.31 and a 200-day moving average price of $314.89. Bio-Rad Laboratories has a twelve month low of $236.73 and a twelve month high of $396.23.

Bio-Rad Laboratories News Roundup

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported Q3 earnings of $2.65 per share, above estimates, while revenue of $656.4 million also exceeded expectations. EPS rose from $2.26 a year earlier, though revenue increased just 0.5%. Article: Bio-Rad Laboratories Q3 Earnings Top Estimates
• Positive Sentiment: The company expanded its oncology assay menu for QX700 digital droplet PCR systems, adding to its product offering. Article: Bio-Rad Expands Oncology Assay Menu for QX700 ddPCR Systems
• Negative Sentiment: Bio-Rad reaffirmed 2026 currency-neutral revenue growth guidance of -3% to 0.5%, signaling limited near-term sales growth. It did target the upper half of its 10%–12% non-GAAP operating-margin range, which offers some support, but the restrained revenue outlook may temper the earnings beat. Article: Bio-Rad Reaffirms 2026 Revenue Growth and Margin Targets

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Citigroup boosted their target price on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Wells Fargo & Company upped their target price on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada increased their target price on shares of Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $343.33.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.